U.S. patent application number 11/198532 was filed with the patent office on 2006-02-16 for perfume composition having a sedative effect.
This patent application is currently assigned to TAKASAGO INTERNATIONAL CORPORATION. Invention is credited to Satomi Kunieda, Yoshiaki Numata, Jonathan Warr.
Application Number | 20060035796 11/198532 |
Document ID | / |
Family ID | 34947267 |
Filed Date | 2006-02-16 |
United States Patent
Application |
20060035796 |
Kind Code |
A1 |
Warr; Jonathan ; et
al. |
February 16, 2006 |
Perfume composition having a sedative effect
Abstract
The present invention provides a perfume composition, which
comprises at least one trimethoxybenzene in an amount of less than
0.5% by weight based on the total weight of the perfume
composition. The present invention also provides a method for
providing sedation in a subject, which comprises applying a perfume
composition comprising at least one trimethoxybenzene in an amount
of less than 0.5% by weight based on the total weight of the
perfume composition to the subject.
Inventors: |
Warr; Jonathan; (Paris,
FR) ; Kunieda; Satomi; (Hiratsuka-shi, JP) ;
Numata; Yoshiaki; (Hiratsuka-shi, JP) |
Correspondence
Address: |
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON
DC
20037
US
|
Assignee: |
TAKASAGO INTERNATIONAL
CORPORATION
|
Family ID: |
34947267 |
Appl. No.: |
11/198532 |
Filed: |
August 8, 2005 |
Current U.S.
Class: |
510/101 |
Current CPC
Class: |
A61Q 13/00 20130101;
A61K 8/33 20130101 |
Class at
Publication: |
510/101 |
International
Class: |
C11D 3/50 20060101
C11D003/50 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 6, 2004 |
FR |
04/08726 |
Claims
1. A perfume composition, which comprises at least one
trimethoxybenzene in an amount of less than 0.5% by weight based on
the total weight of the perfume composition.
2. The perfume composition according to claim 1, which comprises
0.01 to 0.4% by weight of the trimethoxybenzene, based on the total
weight of the perfume composition.
3. The perfume composition according to claims 1, wherein the
trimethoxybenzene is 1,3,5-trimethoxybenzene.
4. The perfume composition according to claims 2, wherein the
trimethoxybenzene is 1,3,5-trimethoxybenzene.
5. A method for providing sedation in a subject, which comprises
applying a perfume composition comprising at least one
trimethoxybenzene in an amount of less than 0.5% by weight based on
the total weight of the perfume composition to the subject.
6. The method according to claim 5, wherein the amount of the
trimethoxybenzene is from 0.01 to 0.4% by weight based on the total
weight of the perfume composition.
7. The method according to claims 5, wherein the trimethoxybenzene
is 1,3,5-trimethoxybenzene.
8. The method according to claims 6, wherein the trimethoxybenzene
is 1,3,5-trimethoxybenzene.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a perfume composition
having a sedative effect, and a method for providing sedation in a
subject.
BACKGROUND OF THE INVENTION
[0002] A number of symptoms result from stress encountered in daily
life, including insomnia.
[0003] In order to deal with such stress, the sedative capacity of
natural essential oils, such as lavender oil or camomile oil, has
been used for a very long time.
[0004] However, these essential oils contain other compounds which
have no sedative effect and are in general employed for their
perfuming capacity.
[0005] The application of such oils is therefore limited by their
perfuming capacity which may not be acceptable for stressed
subjects, who do not like the perfume of these essential oils.
[0006] It has therefore appeared necessary to find sedative agents
that may be used in all kinds of perfume compositions, without
affecting the perfuming capacity of these compositions.
[0007] Synthetic chemical compounds as sedative agents for perfumes
have been already proposed.
[0008] U.S. Pat. No. 5,141,921 describes perfume compositions
containing 3-methyl-hexenoic acid and/or 7-octenoic acid.
[0009] These compositions give rise to psychological effects on
users, such as stimulant and/or sedative effects.
[0010] U.S. Pat. No. 6,268,333 describes the use of
1,3-dimethoxy-5-methylbenzene as a sedative agent in perfumes.
[0011] JP Patent application 2000-86478 describes sedative aromatic
compounds containing 0.5 to 50% by weight of a trialkoxybenzene
represented by formula (I): ##STR1## wherein R.sub.1, R.sub.2 and
R.sub.3, which may be the same or different, preferably same and
each represents CH.sub.3 or C.sub.2H.sub.5.
SUMMARY OF THE INVENTION
[0012] It has now been found, in a surprising way, that
trimethoxybenzenes, which are compounds represented by the above
formula (I), wherein R.sub.1, R.sub.2 and R.sub.3, each represents
a methyl group, give rise to a sedative effect when they are used
in an amount of less than 0.5% by weight based on the total weight
of the perfume composition.
[0013] The present invention therefore has as its objects
[0014] (1) a perfume composition, which comprises at least one
trimethoxybenzene in an amount of less than 0.5% by weight based on
the total weight of the perfume composition;
[0015] (2) the perfume composition according to 1 above, which
comprises 0.01 to 0.4% by weight of the trimethoxybenzene, based on
the total weight of the perfume composition;
[0016] (3) the perfume composition according to 1 or 2 above,
wherein the trimethoxybenzene is 1,3,5-trimethoxybenzene;
[0017] (4) a method for providing sedation in a subject, which
comprises applying a perfume composition comprising at least one
trimethoxybenzene in an amount of less than 0.5% by weight based on
the total weight of the perfume composition to the subject;
[0018] (5) the method according to 4 above, wherein the amount of
the trimethoxybenzene is from 0.01 to 0.4% by weight based on the
total weight of the perfume composition; and
[0019] (6) the method according to 4 or 5 above, wherein the
trimethoxybenzene is 1,3,5-trimethoxybenzene.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] FIG. 1 is a graph showing CNV amplitude expressed with
respect to a reference sample for perfume composition A.
[0021] FIG. 2 is a graph showing CNV amplitude expressed with
respect to a reference sample for perfume composition B.
DETAILED DESCRIPTION OF THE INVENTION
[0022] According to the present invention, a trimethoxybenzene to
be used is in an amount of less than 0.5% by weight, preferably
0.01 to 0.4% by weight based on the total weight of the perfume
composition.
[0023] It is also possible according to the present invention to
use a mixture of trimethoxybenzenes, provided that the total amount
of trimethoxybenzenes is in an amount of less than 0.5% by weight,
preferably 0.01 to 0.4% by weight, based on the total weight of the
perfume composition.
[0024] In addition, among the trimethoxybenzenes to be used in the
present invention, 1,3,5-trimethoxybenzene is preferable.
[0025] Trimethoxybenzenes can be obtained from commercial sources.
They can easily be manufactured via the processes described or
referred to by Wei et al, Organic Preparations and Procedures
International Vol 35 (2003), 225, herein incorporated by
reference.
[0026] The perfume compositions containing trimethoxybenzene
according to the invention comprise at least one trimethoxybenzene
and the other optional ingredient. Specifically, as the example of
the perfume composition, there can be mentioned a perfume
composition which comprises a trimethoxybenzene and a carrier which
is acceptable for the perfume composition.
[0027] As the examples of the carrier which is acceptable for the
perfume composition, solvents which can dissolve the
trimethoxybenzene, such as ethanol, isopropanol, ethylene glycol,
propylene glycol, butylene glycol, pentylene glycol, hexylene
glycol, dipropylene glycol and the like, can be mentioned.
[0028] In the present invention, the expression "sedative effect"
or "sedation" refers to the psychological aspects of well-being and
includes effects of calming, soothing, relaxing, de-stressing
etc.
[0029] In addition, according to the present invention, subjects in
which the sedation is provided are animals, preferably mammals, and
more preferably human.
[0030] The sedative agent according to the present invention is
particularly suitable for perfumes used in toiletries, such as
shampoos, after-shampoos, soaps, bath products, deodorants, body
creams, eau de toilette and hygiene and beauty products.
[0031] In order to obtain the sedative effect, the perfume
composition according to the present invention is preferably in an
amount of from 0.001% to 1% by weight based on the total weight of
the products, for example toiletries, such as shampoos,
after-shampoos, soaps, bath products, deodorants, body creams, eau
de toilette and hygiene and beauty products.
[0032] The sedative effect of trimethoxybenzene is determined by
measuring the variations of negative electrical potential, called
"contingent negative variations" (CNV) according to the method of
Torii [Proceedings of the 19.sup.th Japanese Symposium on Taste and
Smell, 65 (1985)], which is also described in detail in U.S. Pat.
No. 6,268,333.
[0033] The contingent negative variations are small variations in
cerebral potential related to psychological processes, such as
attention, waiting, anticipation etc. as well as being related to
changes in the state of consciousness.
[0034] According to this method, a luminous signal is emitted
approximately 2 seconds after an audible signal, and the subject
must switch off the luminous signal by pressing on the button as
soon as the luminous signal is recognised.
[0035] When carrying out these experiments, a sample to be tested
(perfume composition) or a reference sample (with no smell) is
placed around 10 centimetres from the nose of the subject taking
part in these experiments in such a way as to ensure that the
compound is recognised at all times via the said subject's
respiration.
[0036] An electrode for measuring the contingent negative
variations is placed on the subject's forehead (the reference
electrode is placed on the ear lobe).
[0037] The contingent negative variations measured during an early
period of time going from 400 msec to 1000 msec after the audible
signal and the amplitude of these variations is expressed with
respect to a reference sample to which a value of 100% is
given.
[0038] A sample tested whose amplitude is greater than 100% will be
a stimulant product and a sample tested with an amplitude less than
100% will be a sedative.
[0039] The measurement of contingent negative variations has shown
that trimethoxybenzene, and in particular 1,3,5-trimethoxybenzene,
has a sedative effect when it is used in perfume compositions in an
amount of less than 0.5% by weight, preferably from 0.01% to 0.4%
by weight based on the total weight of the perfume composition.
[0040] The invention will now be described in more detail by the
following illustrative and non-limiting examples:
EXAMPLE 1
Perfume Compositions
[0041] A perfume composition was prepared having a fruity and
floral note of rose, by mixing the following components:
TABLE-US-00001 Ingredients CAS N.degree. % by weight Hedione
24851-98-7 25 Galaxolide .RTM. BB 1222-05-5 15 Lilial .RTM. 80-54-6
10 Phenyl ethyl alcohol 60-12-8 10 Ethyl Linalool 10339-55-6 5 Iso
E Super .RTM. 54464-57-2 5 Cyclohexyl ethyl acetate 21722-83-8 5
Heliobouquet 1205-17-0 2.5 Linalyl acetate 115-97-7 2.5 Habanolide
.RTM. 34902-57-3 2.5 Santalex T .RTM. 68877-29-2 2.5 cis 3-Hexenyl
salicylate 65405-77-8 2.5 Rose absolute (10% in DPG) 8007-01-0 2.5
L-Citronellol 7540-51-4 2.5 Essence of rose 8015-77-8 2 Geraniol
106-24-1 2 Heliotropin 120-57-0 1 Raspberry Ketone (10% in DPG)
5471-51-2 0.5 L-oxide of rose (1% in DPG) 16409-43-1 0.5
Dipropylene glycol (DPG) qsp 100%
[0042] One of the two following were then added, based on the total
weight of the perfume composition:
[0043] 0.4% by weight of 1,3,5-trimethoxybenzene to the above
perfume composition, so as to obtain perfume composition A; or
[0044] 1% by weight of 1,3,5-trimethoxybenzene to the above perfume
composition, obtaining perfume composition B.
EXEMPLE 2
CNV Amplitude
[0045] Five Japanese women took part in the test to determine the
contingent negative variations according to the previously
described experimental method.
[0046] The amplitude of the contingent negative variations was
determined for each woman taking part in the test during the early
period going from 400 msec to 1000 msec after the audible
signal.
[0047] FIGS. 1 and 2 represent graphically CNV amplitude expressed
with respect to a reference sample for perfume composition A (FIG.
1) and for perfume composition B (FIG. 2).
[0048] It was observed, surprisingly, that the
1,3,5-trimethoxybenzene in an amount of 0.4% by weight (perfume
composition A) also had a sedative effect like
1,3,5-trimethoxybenzene in an amount of 1% by weight (perfume
composition B according to the prior art).
[0049] This application is based on French patent application No.
04/08726 filed on Aug. 6, 2004, the entire contents thereof being
hereby incorporated by reference.
* * * * *